首页> 外国专利> A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130

A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130

机译:选择受体复合物包括gp 130的激素的超激动剂,拮抗剂和超拮抗剂的方法

摘要

It has been found that the ligands of the group of cytokins similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce formation of a receptor complex of which the membrane molecule gp 130 is a part. It is thus possible to formulate the hypothesis that two different surfaces of the protein (in this class of hormones), known as site 1 and site 2, bind to two different molecules: site 1 to the specific receptor and site 2 to gp 130. The invention allows the identification of these sites and the isolation of variants having, with respect to the wild hormone, a greater affinity for the specific receptor (superagonists and superantagonists) or affinity for gp 130 reduced or abolished (antagonists and superantagonists). The figure shows the construct pHen DELTA hIL-6 and the production of phasmidic particles that can be used to select agonists of Interleukin 6.
机译:已发现类似于白介素6(IL-6)的细胞因子组的配体,即制瘤素M(OSM),白血病抑制因子(LIF),睫状神经营养因子(CNTF)和白介素11(IL-11) )诱导膜分子gp 130为一部分的受体复合物的形成。因此有可能提出这样的假设,即蛋白质的两个不同表面(在这类激素中)称为位点1和位点2与两个不同分子结合:位点1与特定受体结合,位点2与gp 130结合。本发明允许鉴定这些位点,并分离出相对于野生激素具有对特定受体的更大亲和力(超激动剂和超拮抗剂)或对gp 130的亲和力降低或消除的变体(拮抗剂和超拮抗剂)。该图显示了构建体pHen DELTA hIL-6和可用于选择白介素6激动剂的phasmidic颗粒的产生。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号